Alpha Tau Medical (DRTS) News
NASDAQ: DRTSHealth CareMedical/Dental InstrumentsUSD
11.76+0.445 (+3.93%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DRTS news summary
We found 10 recent headlines mentioning Alpha Tau Medical (DRTS): 5 in the past week and 7 in the past 30 days, most often from GlobeNewswire, Nasdaq, Seeking Alpha. For price context, DRTS is up 3.93% at $11.76. The most recent story, "Alpha Tau Medical GAAP EPS of -$0.39", was published by Seeking Alpha on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Alpha Tau Medical headlines
- Alpha Tau Medical GAAP EPS of -$0.39Seeking Alpha
- Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate UpdateAlpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- Why is Alpha Tau Medical stock surging today?Investing.com
- Alpha Tau Reports Positive Data From Alpha DaRT Recurrent Glioblastoma Trial; Shares Rise(RTTNews) - Alpha Tau Medical Ltd. (DRTS) announced positive updated interim results from the REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial of Alpha DaRT for patients with…NasdaqDRTS, ET
- Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adver- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment…GlobeNewswire
- Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN TrialAlpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN TrialGlobeNewswire
- Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock ExchangeAlpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock ExchangeGlobeNewswire
- Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in KoreaAlpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in KoreaGlobeNewswire
- Alpha Tau Gains FDA Approval For REGAIN Trial Expansion In Recurrent Glioblastoma; Shares Rise(RTTNews) - Alpha Tau Medical Ltd. (DRTS), an Israel-based oncology therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption…NasdaqDRTS, BF.A
- Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual MeetingAlpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual MeetingGlobeNewswire